Company / Operating Income
Denali Therapeutics Inc. Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$555.3M
FY2025
5-year range
-$555.3M / $62.7M
FY2021-FY2025
Trend
-14.0%
vs FY2024
Sector context
#190 of 204
Health Care
What the data says
Among 204 Health Care companies, Denali Therapeutics Inc. is in the bottom 7% for operating income. Operating Income has declined for 3 consecutive years, from $63M in FY2022 to -$555M in FY2025.
Based on SEC 10-K filings.
-$555M in FY2025.
Declined from -$197M to -$555M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 7% in Health CareTop 93% of 204This company -$555.3M Sector average $107.8M
▼
-615.4% below sector average
Key checks
Key Insights
- Denali Therapeutics Inc.'s operating income has declined for 3 consecutive years.
- In FY2025, operating income decreased 14.0% year-over-year.
- Ranks #190 out of 204 companies in the Health Care sector.
- Peak operating income was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.73 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$555.3M | -14.0% |
| FY2024 | -$487.3M | -147.8% |
| FY2023 | -$196.7M | -413.6% |
| FY2022 | $62.7M | +129.4% |
| FY2021 | -$213.2M | -359.7% |
| FY2020 | -$46.4M | +48.6% |
| FY2019 | -$90.1M | -3.1% |
| FY2018 | -$87.4M | +3.0% |
| FY2017 | -$90.1M | -3.1% |
| FY2016 | -$87.4M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026